Recombinant Human TRANCE/RANK L/TNFSF11 Protein, CF 390-TN-010/CF from R&D Systems, a Bio-Techne Brand

Product Specs
ItemRecombinant Human TRANCE/RANK L/TNFSF11 Protein, CF
CompanyR&D Systems, a Bio-Techne Brand
Price $415.00Supplier Page View Company Product Page
Catalog Number390-TN-010/CF
SpeciesHuman
FormatLyophilized from a 0.2 µm filtered solution in MOPS and NaCl with Trehalose
Size10 ug
Molecule NameTRANCE/TNFSF11/RANK L
Purity>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
Molecular WeightObserved: 35 kDa, reducing conditions
Theoretical: 23 kDa
ApplicationsBioactivity
Conjugate/TagUnconjugated
Source/Expression SystemNS0-derived Recombinant Human TRANCE/RANK L/TNFSF11 Protein, CF
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution
NCBI Full Gene NameTNF superfamily member 11
NCBI Gene AliasesCD254, ODF, OPGL, OPTB2, RANKL, TNLG6B, TRANCE, hRANKL2, sOdf

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) A synbiotic medical food improves gut barrier function, reduces immune responses, and inhibits osteoclast activity in models of postmenopausal bone loss aligned with clinical outcomesJournal of Functional FoodsJanuary 26, 2026Ryan S. Green, Tyler Roy, Daniela Diaz-Infante Morales, Claire Morrow, Ryan Neilson, Eric M. Schott, Mark R. Charbonneau, Alicia E. Ballok, Katherine J. Motyl, Gerardo V. ToledoMerck KGAG, Darmstadt, Germany), 1X Pen-Strep (CAT# 15140122, Thermo Fisher; Waltham, MA), RANKL (CAT# 390-TN-010/CF, R&D systems, Minneapolis, MN), M-CSF (CAT# 216-MC-010, R&D systems, Minneapolis, MN). The media mixture

(2) Evaluating the osteoclastogenic potential of peripheral blood mononuclear cells in children with chronic nonbacterial osteomyelitisJBMR PlusJanuary 9, 2026Jacqueline P Bui, Jacob M Curry, Jessica M Kent, Ian M Hurford, Laura Fullbright, Payton Danosky, Kellen Sanders, Sriya Paluvayi, Wendy Garcia, Alejandra M Ruppe, et al.albumin) in 96-well plates, and incubated for 24 h to allow adherence. About 30 ng/mL RANKL (R&D Systems 390-TN-010/CF Recombinant Human TRANCE/RANK L/TNFSF11 Protein) was added into each well except for negative control

(3) Rheumatoid arthritis severity is mediated by crosstalk between synoviocytes and mature osteoclasts through a calcium and cytokine feedback loopExperimental & molecular medicineFebruary 1, 2025Lee ES, Kim HJ, Lee D, Kang JY, Shin DM, Hong JH.culturing them in α-MEM supplemented with 1% p/s, 10% FBS, M-CSF (315-02, PeproTech, 30 ng/ml) and RANKL (390-TN-010/CF, R&D Systems) for 7 days. The culture medium was replaced every 2 days. Fluorescence-activated cell sorting

(4) Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone lossCell researchJanuary 1, 2025Fu W, Chen M, Wang K, Chen Y, Cui Y, Xie Y, Lei ZN, Hu W, Sun G, Huang G, et al.Biolegend) for 3 days, and switched to the differentiation medium including 20 ng/mL M-CSF, 50 ng/mL RANKL (390-TN-010/CF, R&D Systems), with or without 10 nM or 10 µM dexamethasone. To differentiate Raw264.7 cells to osteoclasts,

(5) Zoledronic acid generates a spatiotemporal effect to attenuate osteoarthritis by inhibiting potential Wnt5a-associated abnormal subchondral bone resorptionPloS oneJanuary 1, 2022Ding D, Wang L, Yan J, Zhou Y, Feng G, Ma L, Yang Y, Pei X, Jin Q.

(6) RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone modelJournal of tissue engineeringJanuary 1, 2022Pape J, Bakkalci D, Hosni RA, Simpson BS, Heikinheimo K, Fedele S, Cheema U.

(7) Metformin attenuates osteoclast-mediated abnormal subchondral bone remodeling and alleviates osteoarthritis via AMPK/NF-κB/ERK signaling pathwayPloS oneJanuary 1, 2021Guo H, Ding D, Wang L, Yan J, Ma L, Jin Q.

(8) CD14⁺CD16^- monocytes are the main precursors of osteoclasts in rheumatoid arthritis via expressing Tyro3TKArthritis research & therapySeptember 21, 2020Xue J, Xu L, Zhu H, Bai M, Li X, Zhao Z, Zhong H, Cheng G, Li X, Hu F, et al.

(9) MiRNA-483-5p is involved in the pathogenesis of osteoporosis by promoting osteoclast differentiationMolecular and cellular probesFebruary 1, 2020Li K, Chen S, Cai P, Chen K, Li L, Yang X, Yi J, Luo X, Du Y, Zheng H.

(10) Environmental arginine controls multinuclear giant cell metabolism and formationNature communicationsJanuary 22, 2020Brunner JS, Vulliard L, Hofmann M, Kieler M, Lercher A, Vogel A, Russier M, Brüggenthies JB, Kerndl M, Saferding V, et al.

(11) Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polypsMucosal immunologyJanuary 1, 2020Ogasawara N, Poposki JA, Klingler AI, Tan BK, Hulse KE, Stevens WW, Peters AT, Grammer LC, Welch KC, Smith SS, et al.

(12) Promotion of osteoclastogenesis by IL-26 in rheumatoid arthritisArthritis research & therapyDecember 12, 2019Lee KA, Kim KW, Kim BM, Won JY, Min HK, Lee DW, Kim HR, Lee SH.

(13) Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomasBreast cancer research : BCRDecember 3, 2019Zoi I, Karamouzis MV, Xingi E, Sarantis P, Thomaidou D, Lembessis P, Theocharis S, Papavassiliou AG.

(14) 6-Shogaol Suppresses 2-Amino-1-Methyl-6-Phenylimidazo [4,5-b] Pyridine (PhIP)-Induced Human 786-O Renal Cell Carcinoma Osteoclastogenic Activity and Metastatic PotentialNutrientsSeptember 28, 2019Yeh IJ, Chen SC, Yen MC, Wu YH, Hung CH, Kuo PL.

(15) Oestrogen-deficiency induces bone loss by modulating CD14⁺ monocyte and CD4⁺ T cell DR3 expression and serum TL1A levelsBMC musculoskeletal disordersJuly 12, 2019Collins FL, Stone MD, Turton J, McCabe LR, Wang ECY, Williams AS.

(16) GPDPLQ₁₂₃₇-A Type II Collagen Neo-Epitope Biomarker of Osteoclast- and Inflammation-Derived Cartilage Degradation in vitroScientific reportsFebruary 28, 2019Löfvall H, Katri A, Dąbrowska A, Karsdal MA, Luo Y, He Y, Manon-Jensen T, Dziegiel MH, Bay-Jensen AC, Thudium CS, et al.

(17) Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid ArthritisArthritis & rheumatology (Hoboken, N.J.)September 1, 2018Kjelgaard-Petersen CF, Platt A, Braddock M, Jenkins MA, Musa K, Graham E, Gantzel T, Slynn G, Weinblatt ME, Karsdal MA, et al.

(18) Septins are critical regulators of osteoclastic bone resorptionScientific reportsAugust 29, 2018Møller AMJ, Füchtbauer EM, Brüel A, Andersen TL, Borggaard XG, Pavlos NJ, Thomsen JS, Pedersen FS, Delaisse JM, Søe K.

(19) An anti-TL1A antibody for the treatment of asthma and inflammatory bowel diseasemAbsMay 1, 2018Clarke AW, Poulton L, Shim D, Mabon D, Butt D, Pollard M, Pande V, Husten J, Lyons J, Tian C, et al.

(20) RANKL Inhibits the Production of Osteoprotegerin from Smooth Muscle Cells under Basal Conditions and following Exposure to Cyclic StrainJournal of vascular researchJanuary 1, 2018Davenport C, Harper E, Rochfort KD, Forde H, Smith D, Cummins PM.

Be the First to Write a Review!

TRANCE/TNFSF11/RANK L Protein

TRANCE/TNFSF11/RANK L Protein

TRANCE/TNFSF11/RANK L Protein

Recombinant Human TRANCE/RANK L/TNFSF11 Protein, CF from R&D Systems, a Bio-Techne Brand

Description

R&D Systems, a Bio-Techne Brand

Citations (43)

Reviews

Recombinant Human TRANCE/RANK L/TNFSF11 Protein, CF from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map